Arts industry gets $135 million boost as JobKeeper end looms – Yahoo Finance Australia

Topline data expected in the first half of 2021UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung…

Click here to view the original article.